Development of a Highly Selective NanoBRET Probe to Assess MAGL Inhibition in Live Cells
ChemBioChem · 2025
DOI: 10.1002/cbic.202400704 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemBioChem, 2025. Verfasst von Thais Gazzi und 23 weiteren Autor:innen. Beteiligte Einrichtung: Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Berlin, Germany. Hauptthemen laut MEDLINE: Boron Compounds, Fluorescent Dyes, Enzyme Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Cell‐free enzymatic assays are highly useful tools in early compound profiling due to their robustness and scalability. However, their inadequacy to reflect the complexity of target engagement in a cellular environment may lead to a significantly divergent pharmacology that is eventually observed in cells. The discrepancy that emerges from properties like permeability and unspecific protein binding may largely mislead lead compound selection to undergo further chemical optimization. We report the development of a new intracellular NanoBRET assay to assess MAGL inhibition in live cells. Based on a reverse design approach, a highly potent, reversible preclinical inhibitor was conjugated to the cell‐permeable BODIPY590 acceptor fluorophore while retaining its overall balanced properties. An engineered MAGL‐nanoluciferase (Nluc) fusion protein provided a suitable donor counterpart for the facile interrogation of intracellular ligand activity. Validation of assay conditions using a selection of known MAGL inhibitors set the stage for the evaluation of over 1’900 MAGL drug candidates derived from our discovery program. This evaluation enabled us to select compounds for further development based not only on target engagement, but also on favorable physicochemical parameters like permeability and protein binding. This study highlights the advantages of cell‐based target engagement assays for accelerating compound profiling and progress at the early stages of drug discovery programs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Berlin, Germany.
- Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, Basel, 4070, Switzerland.
ORCID-Profile: Thais Gazzi, Luca Gobbi, Matthias B Wittwer, Bernd Kuhn, Marc Nazaré
Zitieren
APA
Gazzi, T., Brennecke, B., Olikauskas, V., Hochstrasser, R., Wang, H., Keen Chao, S., Atz, K., Mostinski, Y., Topp, A., Heer, D., Kaufmann, I., Ritter, M., Gobbi, L., Hornsperger, B., Wagner, B., Richter, H., O'Hara, F., Wittwer, M. B., Jul Hansen, D., …, & Nazaré, M. (2025). Development of a Highly Selective NanoBRET Probe to Assess MAGL Inhibition in Live Cells. ChemBioChem. https://doi.org/10.1002/cbic.202400704
Vancouver
Gazzi T, Brennecke B, Olikauskas V, Hochstrasser R, Wang H, Keen Chao S, et al. Development of a Highly Selective NanoBRET Probe to Assess MAGL Inhibition in Live Cells. ChemBioChem. 2025. doi:10.1002/cbic.202400704
BibTeX
@article{Gazzi2025,
author = {Gazzi, Thais and Brennecke, Benjamin and Olikauskas, Valentas and Hochstrasser, Remo and Wang, Haiyan and Keen Chao, Suzan and Atz, Kenneth and Mostinski, Yelena and Topp, Andreas and Heer, Dominik and Kaufmann, Isabelle and Ritter, Martin and Gobbi, Luca and Hornsperger, Benoit and Wagner, Bjoern and Richter, Hans and O'Hara, Fionn and Wittwer, Matthias B and Jul Hansen, Dennis and Collin, Ludovic and Kuhn, Bernd and Benz, Joerg and Grether, Uwe and Nazaré, Marc},
title = {Development of a Highly Selective NanoBRET Probe to Assess MAGL Inhibition in Live Cells},
journal = {ChemBioChem},
year = {2025},
doi = {10.1002/cbic.202400704}
}
EUVIMED